Recent studies reveal that GLP-1 receptor agonists like Ozempic, used for weight loss and diabetes, could also diminish opioid overdose and alcohol use disorders. This finding parallels past discoveries in hepatitis C treatments, which emerged unexpectedly during HIV research trials. There is excitement in the medical community about the potential of these weight loss medications to tap into the brain's reward pathways, causing positive shifts in both eating behaviors and substance use. As such medications gain attention, their dual purpose presents new avenues in addiction treatment strategies.
Sometimes, new effective treatment medications are discovered almost by accident. This happened with the new generation of hepatitis C medications…
Collection
[
|
...
]